Thursday Sector Laggards: Services, Healthcare
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2025
0mins
Should l Buy DGX?
Source: NASDAQ.COM
Services and Healthcare Sector Performance: As of midday Thursday, the Services sector is underperforming with notable losses from Tractor Supply Co. and Chipotle Mexican Grill, while the Healthcare sector also shows declines in major stocks like Abbott Laboratories and Quest Diagnostics.
ETF Tracking and Year-to-Date Performance: The iShares U.S. Consumer Services ETF is up 0.8% today but down year-to-date, while the Health Care Select Sector SPDR ETF is slightly up for the day but down overall this year; both sectors have mixed performances among their key stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 191.420
Low
190.00
Averages
203.33
High
210.00
Current: 191.420
Low
190.00
Averages
203.33
High
210.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quest Diagnostics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Quest Diagnostics reported Q4 revenues of $2.81 billion, reflecting a 7.1% year-over-year increase, exceeding analysts' expectations by 1.9%, indicating robust performance amid stable demand that is likely to bolster market confidence.
- Industry Performance: The testing and diagnostics services sector collectively surpassed analysts' consensus estimates by 2.1%, supported by stable revenue streams and the demand from an aging population, despite facing pricing pressures and regulatory compliance challenges.
- Market Reaction: Despite Quest's strong earnings, the stock price has remained flat since the report, currently trading at $192.85, reflecting market uncertainty regarding future growth, which may impact investor confidence.
- Future Outlook: With the expansion of personalized medicine and the adoption of rapid testing, the industry's outlook is optimistic; however, vigilance is needed regarding reimbursement uncertainties and increasing competition, making continuous investment in new technologies crucial for sustaining growth.
See More
Quest Diagnostics to Report Q1 2026 Financial Results on April 21
- Earnings Release Schedule: Quest Diagnostics will report its Q1 2026 financial results on April 21, 2026, before market open, which is expected to significantly impact investors and the market.
- Conference Call Details: The company will hold a conference call at 8:30 a.m. Eastern Time on the same day, allowing investors to dial in at 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) to receive timely financial information.
- Replay Access: A replay of the conference call will be available starting at 10:30 a.m. Eastern Time on April 21, 2026, until midnight on May 5, providing a convenient way for investors who missed the live event to access key information.
- Company Background: Quest Diagnostics plays a crucial role in the U.S. healthcare sector, serving one in three American adults annually, emphasizing its strategic significance in improving health management and disease identification.
See More
Quest Launches AI Companion to Analyze Lab Data
- AI Companion Feature: Quest Diagnostics has launched the Quest AI Companion, powered by Google's Gemini technology, which analyzes up to five years of personal lab data to help users understand test results and identify potential health risks, thereby enhancing communication efficiency between patients and healthcare providers.
- User Experience Enhancement: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their results through simple inquiries, thus avoiding the privacy risks associated with uploading personal health data to public AI platforms and increasing user trust in data security.
- Strategic Collaboration: The strategic partnership between Quest and Google Cloud was established in March 2025, aiming to integrate advanced AI technologies to optimize data management and customer experience, with plans for continued collaboration to drive healthcare innovation and improve service quality for patients and providers.
- Market Demand Response: Despite the growing prevalence of AI technologies in healthcare, a Quest survey indicates that most individuals are cautious about using public AI applications to analyze personal health data; the launch of Quest AI Companion addresses patients' needs for privacy and data security, helping them better understand their lab data.
See More
Quest Launches AI Companion for Lab Data Analysis
- AI Companion Launch: Quest Diagnostics introduces Quest AI Companion, powered by Google's Gemini technology, which helps users analyze up to five years of lab data to identify potential health risks, thereby enhancing user engagement and proactive health management.
- Enhanced User Experience: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their lab results through simple inquiries, which improves communication efficiency between patients and healthcare providers.
- Data Security Assurance: Operating within the HIPAA-compliant MyQuest platform, Quest AI Companion alleviates concerns about uploading personal health data to public AI platforms, effectively safeguarding privacy and increasing user trust.
- Deepened Strategic Partnership: The strategic collaboration between Quest and Google Cloud, established in March 2025, aims to optimize data management and customer experience through the integration of advanced AI technologies, with plans to continue driving healthcare innovation.
See More
DIGI POWER X ADVANCES TO CBOE CANADA
- Graduation Announcement: DIGI POWER X graduates are set to become part of the Canadian workforce, marking a significant milestone in their educational journey.
- Program Impact: The program aims to equip graduates with essential skills and knowledge to thrive in the energy sector, contributing to Canada's growing demand for skilled professionals.
- Future Opportunities: Graduates are expected to explore various career paths within the energy industry, enhancing their prospects in a competitive job market.
- Community Engagement: The graduation event highlights the importance of community support and collaboration in fostering educational initiatives and workforce development.
See More
Quest Diagnostics Appoints New Chief Strategy and M&A Officer
- Executive Appointment: Quest Diagnostics has appointed Benjamin Beauvalot as Senior Vice President and Chief Strategy and M&A Officer, responsible for developing the company's growth strategy and leading mergers and acquisitions, which is expected to drive further advancements in the healthcare sector.
- Extensive Experience: Beauvalot brings over 20 years of experience in business strategy and transformation, having held executive roles at Danaher and Patheon where he successfully implemented numerous M&A and integration strategies, enhancing his expertise in the healthcare services field.
- Leadership Transition: Beauvalot succeeds Dermot Shorten, who has held the position since 2008 and oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories, establishing a solid foundation for the company.
- Strategic Vision: The new Chief Strategy Officer's appointment aims to leverage his rigorous approach to business integration to further propel Quest Diagnostics' organic and acquisitive growth, supporting the company's mission to create a healthier world.
See More
Quest Diagnostics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Quest Diagnostics reported Q4 revenues of $2.81 billion, reflecting a 7.1% year-over-year increase, exceeding analysts' expectations by 1.9%, indicating robust performance amid stable demand that is likely to bolster market confidence.
- Industry Performance: The testing and diagnostics services sector collectively surpassed analysts' consensus estimates by 2.1%, supported by stable revenue streams and the demand from an aging population, despite facing pricing pressures and regulatory compliance challenges.
- Market Reaction: Despite Quest's strong earnings, the stock price has remained flat since the report, currently trading at $192.85, reflecting market uncertainty regarding future growth, which may impact investor confidence.
- Future Outlook: With the expansion of personalized medicine and the adoption of rapid testing, the industry's outlook is optimistic; however, vigilance is needed regarding reimbursement uncertainties and increasing competition, making continuous investment in new technologies crucial for sustaining growth.
See More
Quest Diagnostics to Report Q1 2026 Financial Results on April 21
- Earnings Release Schedule: Quest Diagnostics will report its Q1 2026 financial results on April 21, 2026, before market open, which is expected to significantly impact investors and the market.
- Conference Call Details: The company will hold a conference call at 8:30 a.m. Eastern Time on the same day, allowing investors to dial in at 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) to receive timely financial information.
- Replay Access: A replay of the conference call will be available starting at 10:30 a.m. Eastern Time on April 21, 2026, until midnight on May 5, providing a convenient way for investors who missed the live event to access key information.
- Company Background: Quest Diagnostics plays a crucial role in the U.S. healthcare sector, serving one in three American adults annually, emphasizing its strategic significance in improving health management and disease identification.
See More
Quest Launches AI Companion to Analyze Lab Data
- AI Companion Feature: Quest Diagnostics has launched the Quest AI Companion, powered by Google's Gemini technology, which analyzes up to five years of personal lab data to help users understand test results and identify potential health risks, thereby enhancing communication efficiency between patients and healthcare providers.
- User Experience Enhancement: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their results through simple inquiries, thus avoiding the privacy risks associated with uploading personal health data to public AI platforms and increasing user trust in data security.
- Strategic Collaboration: The strategic partnership between Quest and Google Cloud was established in March 2025, aiming to integrate advanced AI technologies to optimize data management and customer experience, with plans for continued collaboration to drive healthcare innovation and improve service quality for patients and providers.
- Market Demand Response: Despite the growing prevalence of AI technologies in healthcare, a Quest survey indicates that most individuals are cautious about using public AI applications to analyze personal health data; the launch of Quest AI Companion addresses patients' needs for privacy and data security, helping them better understand their lab data.
See More
Quest Launches AI Companion for Lab Data Analysis
- AI Companion Launch: Quest Diagnostics introduces Quest AI Companion, powered by Google's Gemini technology, which helps users analyze up to five years of lab data to identify potential health risks, thereby enhancing user engagement and proactive health management.
- Enhanced User Experience: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their lab results through simple inquiries, which improves communication efficiency between patients and healthcare providers.
- Data Security Assurance: Operating within the HIPAA-compliant MyQuest platform, Quest AI Companion alleviates concerns about uploading personal health data to public AI platforms, effectively safeguarding privacy and increasing user trust.
- Deepened Strategic Partnership: The strategic collaboration between Quest and Google Cloud, established in March 2025, aims to optimize data management and customer experience through the integration of advanced AI technologies, with plans to continue driving healthcare innovation.
See More
DIGI POWER X ADVANCES TO CBOE CANADA
- Graduation Announcement: DIGI POWER X graduates are set to become part of the Canadian workforce, marking a significant milestone in their educational journey.
- Program Impact: The program aims to equip graduates with essential skills and knowledge to thrive in the energy sector, contributing to Canada's growing demand for skilled professionals.
- Future Opportunities: Graduates are expected to explore various career paths within the energy industry, enhancing their prospects in a competitive job market.
- Community Engagement: The graduation event highlights the importance of community support and collaboration in fostering educational initiatives and workforce development.
See More
Quest Diagnostics Appoints New Chief Strategy and M&A Officer
- Executive Appointment: Quest Diagnostics has appointed Benjamin Beauvalot as Senior Vice President and Chief Strategy and M&A Officer, responsible for developing the company's growth strategy and leading mergers and acquisitions, which is expected to drive further advancements in the healthcare sector.
- Extensive Experience: Beauvalot brings over 20 years of experience in business strategy and transformation, having held executive roles at Danaher and Patheon where he successfully implemented numerous M&A and integration strategies, enhancing his expertise in the healthcare services field.
- Leadership Transition: Beauvalot succeeds Dermot Shorten, who has held the position since 2008 and oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories, establishing a solid foundation for the company.
- Strategic Vision: The new Chief Strategy Officer's appointment aims to leverage his rigorous approach to business integration to further propel Quest Diagnostics' organic and acquisitive growth, supporting the company's mission to create a healthier world.
See More
